Galera Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of therapeutics that have the potential to transform radiotherapy in cancer. Co. utilizes its capabilities in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Co.'s product candidate, avasopasem manganese (GC4419), is a highly selective small molecule dismutase mimetic that is developing for the reduction of severe oral mucositis. Co.'s another dismutase mimetic product candidate, GC4711, is to increase the anti-cancer efficacy of stereotactic body radiation therapy. The GRTX stock yearly return is shown above.
The yearly return on the GRTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GRTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|